A detailed history of Inspire Advisors, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Inspire Advisors, LLC holds 25,207 shares of EXEL stock, worth $897,621. This represents 0.09% of its overall portfolio holdings.

Number of Shares
25,207
Previous 20,184 24.89%
Holding current value
$897,621
Previous $453,000 44.37%
% of portfolio
0.09%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$21.96 - $27.6 $110,305 - $138,634
5,023 Added 24.89%
25,207 $654,000
Q2 2024

Aug 08, 2024

BUY
$20.34 - $23.73 $410,542 - $478,966
20,184 New
20,184 $453,000
Q3 2023

Oct 26, 2023

BUY
$19.04 - $22.74 $524,418 - $626,327
27,543 New
27,543 $601,000
Q1 2021

Apr 30, 2021

SELL
$20.53 - $25.22 $472 - $580
-23 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$18.39 - $24.8 $422 - $570
23 New
23 $0

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Inspire Advisors, LLC Portfolio

Follow Inspire Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Inspire Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Inspire Advisors, LLC with notifications on news.